Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146191 · ClinicalTrials.gov registry record · Phase 1
RE104 Radiolabeled Mass Balance (hAME) Study
A Phase 1 study, sponsored by Reunion Neuroscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07146191: Completed Phase 1 study, sponsored by Reunion Neuroscience.
NCT07146191 is a Phase 1 study that has completed, run by Reunion Neuroscience. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07146191, a Phase 1 study, has completed, sponsored by Reunion Neuroscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers. This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hours after SC dosing of \[14C\]-RE104.
Interventions
- DRUG 2-[14C]-RE104 for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-08-19 |
| Est. Completion | 2025-10-02 |
| Phase | Phase 1 |
What the finished NCT07146191 record still lists
NCT07146191 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which 2-[14C]-RE104 for Injection is the first listed.
NCT07146191 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07146191 about?
NCT07146191 is a clinical study titled "RE104 Radiolabeled Mass Balance (hAME) Study". The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers. This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hou...
What is the current status of trial NCT07146191?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-08-19. Estimated completion is 2025-10-02.
What interventions are being tested in trial NCT07146191?
The interventions under investigation include: 2-[14C]-RE104 for Injection (DRUG).
Who is sponsoring clinical trial NCT07146191?
This trial is sponsored by Reunion Neuroscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07146191's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI